Roche Faces Pivotal Week as Pipeline Hits and Misses Shape H1 Outlook
Published on 07/17/2026 at 17:25 | Redaktion boerse-global.deRoche enters a defining stretch this week, with the release of first-half 2026 earnings on Thursday, July 23, coming against a backdrop of high-profile clinical successes and a notable setback in its pipeline. Investors are weighing the potential of a new Alzheimer’s therapy and a best-in-class KRAS inhibitor against the abandonment of a long-running Huntington’s disease programme, all while the strong Swiss franc continues to weigh on reported revenue.
On the oncology front, Roche scored a clear win with Divarasib, its KRAS G12C inhibitor. In a Phase III trial, the drug showed statistically significant superiority over already approved KRAS G12C inhibitors in patients with non-small cell lung cancer — a rare head-to-head victory against established targeted therapies. The results, announced via ad-hoc disclosure in early July, mark a significant step forward in Roche’s precision oncology push. Separately, the US Food and Drug Administration accepted a supplemental application for the Lunsumio–Polivy combination in relapsed or refractory large B-cell lymphoma, expanding the haematology franchise. In diagnostics, Roche secured CE marking for a new IGRA-based blood test that aims to improve tuberculosis detection in lab settings.
But the pipeline news is not uniformly positive. Roche and partner Ionis Pharmaceuticals have decided to halt development of Tominersen, an antisense oligonucleotide for Huntington’s disease, after a Phase II study failed to demonstrate clinical superiority over placebo. The decision, made in early July, ends a resource-intensive programme in a therapeutic area with few effective options. Roche countered the disappointment with encouraging data on other fronts: at the Alzheimer’s Association International Conference in London, it unveiled progress on Trontinemab, a potential Alzheimer’s treatment, alongside advances in blood-based diagnostics for early amyloid detection. Analyst David Evans of Kepler Cheuvreux singled out Trontinemab as an overlooked asset, reiterating Roche as his firm’s top pharma pick with a price target of CHF 415.
Should investors sell immediately? Or is it worth buying Roche?
Currency headwinds remain the dominant short-term challenge. In the first quarter, Roche posted currency-adjusted revenue growth of 6%, but nominal sales in Swiss francs fell 5% as the franc appreciated sharply. Chief Executive Thomas Schinecker reaffirmed the full-year guidance at the Q1 presentation, and the half-year report will show whether that momentum held in the second quarter. The market is watching closely to see if the franc’s drag has eased.
Analyst sentiment is mixed. Barclays Capital sticks with an “Overweight” rating and a CHF 410 target, while JPMorgan Chase also rates the stock “Overweight” but with a lower target of CHF 325. the Deutsche Bank adopts a more cautious “Hold” stance at CHF 340. The three-month consensus, according to media reports, leans “Hold.” Technically, the share price shows divergent patterns depending on listing. The euro-traded Roche stock climbed to €362.80 on July 15, crossing above its 50-day moving average for the first time since late June and maintaining a long-term uptrend. The Swiss franc-denominated version dipped below the same moving average on July 14 but has still gained 4.48% since June 4, standing 1.54% above its 200-day line. Over the past week the stock closed at £323.90, with a neutral RSI of 47.2 and a market capitalisation equivalent to €355.34 billion.
With the half-year numbers due before the Swiss market opens on July 23, and fresh analyst commentary on the Alzheimer’s programme already in focus, the coming days carry the potential to define the stock’s near-term trajectory. If Roche can confirm the currency-adjusted growth rate seen in Q1, the prevailing uptrend since June may gain fresh momentum.
Ad
Roche Stock: New Analysis - 17 July
Fresh Roche information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
